Age = 18 years of either gender
Written informed consent must be obtained before any intravitreal injection of bevacizumab is performed
Visual impairment predominantly due to abnormal new vessel ingrowth and/or macular edema. The presence of fluid (intraretinal, subretinal or sub-RPE) detected clinically or on the ocular coherence tomography.

NCT03211741_inc_T1
Person
Age
NCT03211741_inc_T2
Value
= 18 years
NCT03211741_inc_T3
Person
either gender
NCT03211741_inc_T5
Condition
Visual impairment
NCT03211741_inc_T6
Condition
abnormal new vessel ingrowth
NCT03211741_inc_T7
Condition
macular edema
NCT03211741_inc_T8
Qualifier
intraretinal
NCT03211741_inc_T9
Qualifier
subretinal
NCT03211741_inc_T10
Qualifier
sub-RPE
NCT03211741_inc_T11
Procedure
ocular coherence tomography
NCT03211741_inc_T12
Condition
fluid
NCT03211741_inc_T13
Scope
intraretinal, subretinal or sub-RPE
NCT03211741_inc_T14
Scope
abnormal new vessel ingrowth and/or macular edema